>>>>>
You suggested that GTC’s drug candidates have a greater likelihood of immunogenicity than recombinant drugs produced by other means.
<<<<<<
That's a complete fabrication. I never once said anything close to that. I enjoy participating in a healthy debate, but dont cross the line and put words into my mouth in order to bolster your point.
As for my diligence in studying this company, I think I'm asking a pretty fundamental question here that goes to the heart of the matter. How well do their recombinant transgenic milk proteins resemble the material found in plasma? So far, the company has stated that for Atryn, their lead product, the material produced in transgenic goats does not match the dominant form found in plasma, which leads to a shorter in vivo half-life. In this case, they got lucky (and admitted themselves) that decreased half-life doesn't affect the activity of the therapeutic. Now, is this phenomenon the exception, or the norm? This is why I would love to see a slide showing bio-equivalence of a few different proteins expressed in transgenic milk compared to the same proteins expressed in CHO cells (especially Abs). That's what we would call a money slide.
And another thing, the reason why I ignored your claim that GTC Researchers can simply "engineer in" post-translational modificiations is because its not that easy. Trust me, Ive engineered-in and engineered-out N-linked glycosylation signatures on multiple scaffolds. I would gather that its especially dicey for a metastable protein like a serpin, which is basically a molecular mousetrap waiting to catch a protease.
Market Data 
Markets 
AI
